Evidence map›Paper›PMID 24825873›Full record

ArticleOtolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery2014

A cytokine-delivering polymer is effective in reducing tumor burden in a head and neck squamous cell carcinoma murine model.

Yuan Lin, Jie Luo, Weichao Eric Zhu, Minu Srivastava, Dorthe Schaue, David A Elashoff, Steven M Dubinett, Sherven Sharma, Benjamin Wu, Maie A St John

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Nanoformulation of CCL21 greatly increases its effectiveness as an immunotherapy for neuroblastoma.Journal of controlled release : official journal of the Controlled Release Society · 2020
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Yuan LinDepartment of Head and Neck Surgery, University of California, Los Angeles, Los Angeles, California, USA UCLA Head and Neck Cancer Program, University of California, Los Angeles, Los Angeles, California, USA Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Jie LuoDepartment of Head and Neck Surgery, University of California, Los Angeles, Los Angeles, California, USA UCLA Head and Neck Cancer Program, University of California, Los Angeles, Los Angeles, California, USA Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Weichao Eric ZhuDepartment of Bioengineering, University of California, Los Angeles, Los Angeles, California, USA.
Minu SrivastavaDivision of Pulmonary and Critical Care Medicine, Department of Medicine, University of California, Los Angeles, Los Angeles, California, USA Veterans' Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA.
Dorthe SchaueDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, California, USA.
David A ElashoffJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California, USA Department of Biostatistics, University of California, Los Angeles, Los Angeles, California, USA.
Steven M DubinettDivision of Pulmonary and Critical Care Medicine, Department of Medicine, University of California, Los Angeles, Los Angeles, California, USA Veterans' Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California, USA.
Sherven SharmaDivision of Pulmonary and Critical Care Medicine, Department of Medicine, University of California, Los Angeles, Los Angeles, California, USA Veterans' Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA.
Benjamin WuDepartment of Bioengineering, University of California, Los Angeles, Los Angeles, California, USA Division of Advanced Prosthodontics, Biomaterials, and Hospital Dentistry, University of California, Los Angeles, Los Angeles, California, USA Department of Materials Science and Engineering, University of California, Los Angeles, Los Angeles, California, USA Department of Orthopedic Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Maie A St JohnDepartment of Head and Neck Surgery, University of California, Los Angeles, Los Angeles, California, USA UCLA Head and Neck Cancer Program, University of California, Los Angeles, Los Angeles, California, USA Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California, USA mstjohn@mednet.ucla.edu.
University of California, Los Angeles · USVA Greater Los Angeles Healthcare System · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
A Novel Modular Polymer Platform for the Treatment of Oral SCCAK23DE021193 · NIDCR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ST. JOHN, MAIE A. · 2010 to 2014
$633k
NCATS NIH HHS UL1 TR000124NCI NIH HHS P30 CA016042NIDCR NIH HHS K23 DE021193
6 · The paper itself

Abstract

objectiveThis study aimed to evaluate the therapeutic efficacy of a novel polymer platform delivering cisplatin and cytokines in the treatment of head and neck squamous cell carcinoma (HNSCC). STUDY

designIn vivo study.

settingAcademic research laboratory. SUBJECTS AND

methodsMice were randomized to receive implantation of (1) no polymer, (2) plain polymer, (3) plain polymer with local cisplatin injection, or (4) cisplatin polymer. The 2 groups of mice implanted with cisplatin polymer or no polymer were further randomized to receive (1) 4 Grays external beam radiation for 4 days or (2) no radiation. For cytokine studies, mice were grouped into (1) no polymer, (2) plain polymer, (3) plain polymer with intratumoral injection of recombinant CCL21 twice a week, (4) polymer containing parental dendritic cells, or (5) polymer containing dendritic cells secreting CCL21 (DC-CCL21).

resultsThe cisplatin-secreting polymer effectively reduced tumors in the mice by more than 16-fold (P < .01). We also observed a statistically significant lower tumor weight among mice treated with cisplatin polymer and concomitant radiation compared to control groups. The DC-CCL21 polymer reduced SCCVII/SF tumors in the C3H/HeJ mice by more than 41% (P < .01).

conclusionHerein, we demonstrate the efficacy of a novel polymer platform in delivering cisplatin and cytokines. We also demonstrate that we can effectively grow dendritic cells in the polymer that can actively secrete CCL21 for a minimum of 5 days. This polymer may represent a new therapeutic modality for patients with HNSCC. Once this polymer platform is optimized, we will plan to pursue prospective trials in patients with HNSCC.

Indexed as

Drug ImplantsAnalysis of VarianceAnimalsBlotting, WesternCarcinoma, Squamous CellCisplatinCytokinesDisease Models, AnimalDrug Delivery SystemsEnzyme-Linked Immunosorbent AssayFemaleFlow CytometryHead and Neck NeoplasmsImmunohistochemistryMaleMiceCisplatinCytokinesDrug ImplantsPolymershead and neck cancernovel therapeuticspolymersquamous cell carcinoma

Identifiers

PMID24825873
PMCPMC4167678
OpenAlexW2098586505

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.